Pharma Archives - Page 58 of 76 - Life Sciences Times

First Patient Dosed in Phase 3 Trial of Potential Dravet Syndrome Treatment

August 11, 2025

Boston IVF Adds Dr. Mary Morris to Massachusetts Fertility Team, Expanding Expertise in Oncofertility and Family Building

August 7, 2025

Silversmith Capital Partners Closes $1.7 Billion Fund V, Names Sri Rao Managing Partner

July 31, 2025

THIS WEEK'S STORIES

Strand Therapeutics Secures $153 Million in Series B to Accelerate Programmable mRNA Therapy Pipeline

August 7, 2025

First FDA-Approved Treatment for MacTel Administered Following Commercial Launch

August 11, 2025

Ametros Strengthens Leadership Team with Two Key Hires to Enhance Member Services

August 8, 2025

ABOUT US

Life Science Times is New England’s premier life sciences publication, covering the Pharma, Biotech, MedTech and Public Health sectors nationwide with a special focus on New England. Updated daily, we cover the latest news in everything else that touches any rubric of the rapidly growing life sciences industry.

Pharma

Study Points to New Mechanism for Schizophrenia Drug Candidate Evenamide

KalVista Drug for Hereditary Angioedema Keeps Orphan Status in EU

First Patient Dosed in Phase 3 Trial of Potential Dravet Syndrome Treatment

Palleon Pharmaceuticals Doses First Patient in Phase 2 Trial of E-602 for Autoimmune Kidney Disease

Astria Therapeutics Strikes $32 Million Licensing Deal with Kaken Pharmaceutical for HAE Drug in Japan

Most Read

First FDA-Approved Treatment for MacTel Administered Following Commercial Launch

Study Points to New Mechanism for Schizophrenia Drug Candidate Evenamide

FDA Clears Thermo Fisher Test to Match Lung Cancer Patients With Newly Approved HER2-Targeted Drug

SetPoint Medical Secures $140 Million to Advance Rheumatoid Arthritis Therapy, Expands Leadership Team

EDITOR PICKS

First Patient Dosed in Phase 3 Trial of Potential Dravet Syndrome Treatment

Boston IVF Adds Dr. Mary Morris to Massachusetts Fertility Team, Expanding Expertise in Oncofertility and Family Building

Silversmith Capital Partners Closes $1.7 Billion Fund V, Names Sri Rao Managing Partner

THIS WEEK'S STORIES

Strand Therapeutics Secures $153 Million in Series B to Accelerate Programmable mRNA Therapy Pipeline

First FDA-Approved Treatment for MacTel Administered Following Commercial Launch

Ametros Strengthens Leadership Team with Two Key Hires to Enhance Member Services

POPULAR CATEGORY

ABOUT US

FOLLOW US